Latest Conference Articles

During the pandemic, many community pharmacists also gained the authority to provide routine vaccinations for child populations.

Pharmacies should start to prepare for cash flow challenges when the direct and indirect remuneration changes in 2024.

Common assumptions about each generation are often incorrect, according to an expert in generational research.

The results of the study were presented at the 83rd Scientific Sessions of the American Diabetes Association in San Diego, California and were also published in The Lancet.

The American Diabetes Association showcased advancements in diabetes technology revolving around improving glucose control devices and treating diabetic retinopathy at the 83rd Scientific Sessions.

During separate panel discussions at McKesson ideaShare 2023, pharmacists discussed advocacy for pharmacy benefit manager reform and community health worker training.

McKesson also announced the rollout of the Foster & Thrive program and a new Ohio distribution center during the conference.

Pharmacists can recognize evidence of successful interventions and learn how to integrate them into their own practice.

Community health workers can address issues of health equity to enhance the services of the pharmacy and support a value-based care model.

McKesson ideaShare is held from June 22 to June 25 in Las Vegas, Nevada.

Approximately 50% of patients with refractory or relapsed disease achieved complete response following treatment with the Janus kinase 1 (JAK1) inhibitor.

Trial results demonstrated that 58.5% of individuals receiving luspatercept-aamt (Reblozyl; Bristol Myers Squibb) achieved the primary endpoint of red blood cell transfusion independence of at least 12 weeks.

Pharmacists can help patients live a life of meaning and gratitude after cancer recovery.

The single institution study compared fixed dose capecitabine to standard dose capecitabine to compare efficacy and tolerability in metastatic breast cancer.

The benefit of ribociclib was seen as consistent against all of the stratification factors in the phase III study.

Heidi Finnes, PharmD, BCOP, FHOPA, addresses how the study data may impact the treatment of IDH1/2 mutating gliomas going forward.

Panelists discuss the potential impact of the study data presented at the ASCO 2023 Annual Meeting, which led to significant response from the field.

Andre Harvin, PharmD, MBA, discussed the use of immunotherapies in melanoma and broader challenges with access to oncology care in rural or underserved communities.

Ryan Haumschild, PharmD, MS, MBA, discussed his presentation at the Oncology Pharmacists Connect meeting, taking place June 15 through 17 in Austin, Texas.

The ASCO abstracts were on the TALAPRO-2 trial (abstract 5053) and PROpel trial (abstract 5012).

With immune checkpoint inhibitors in particular, patients are seeing greater results with fewer adverse effects.

For squamous cell carcinoma systemic therapy that is not concurrent with radiation therapy, preferred regimens are immune checkpoint inhibitors.

Both immunotherapies and targeted therapies are showing significant promise in these areas, offering patients new treatment options.

Andrea Iannucci, PharmD, BCOP, assistant chief pharmacy officer at UC Davis Health, discussed challenges and opportunities when implementing new treatments for breast cancer.

Heidi Finnes, PharmD, BCOP, FHOPA, director of clinical ambulatory pharmacy practice at Mayo Clinic, discussed updates in melanoma and the use of immunotherapies and targeted therapies.

Earlier in June, Govindan led an educational session about genomic testing at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

The folate alpha receptor (FRα) does have a toxicity profile, but unlike other chemotherapies, it does not severely compromise bone marrow and may improve ability to receive more therapies.

Denise Scarpelli, PharmD, MBA, discussed her presentation at the ASHP 2023 Summer Meeting.